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Design and development of a photoswitchable
DFG-out kinase inhibitor†
Yongjin Xu,a Chunxia Gao,a Liliana Håversen,b Thomas Lundbäck, c
Joakim Andréasson *d and Morten Grøtli *a
We report the synthesis and characterisation of a photoswitchable
DFG-out kinase inhibitor. Photocontrol of the target kinase in both
enzymatic and living cell assays is demonstrated.
Protein kinases play important roles in signal transduction
cascades, regulating different cellular processes such as cell
differentiation, cell proliferation, and apoptosis. Thus, dysre-
gulation of key protein kinases often leads to severe disorders,
including cancer, inflammation, and neuro-degenerative
diseases.1 Furthermore, the role that many kinases play in a
variety of disease states is poorly understood. Reversibility and
temporal control over kinase inhibition will contribute to a
better understanding of kinase function in biological systems.
In addition, the kinase of interest may have a specific function
in an organ or tissue. The ability to regulate the kinase activity
in a site-specific manner will have positive implications in
proving the site of action of the kinase inhibitor, studying cell
signalling, and understanding adverse effects of the inhibitor.
Photopharmacology has become a term for a number of
approaches in which photochemistry and pharmacology are
linked to achieve efficient spatiotemporal control over the
biological activities of small molecules by light.2 One of the
most widely used approaches to modify bioactive molecules
into light-responsive counterparts is integration with molecular
photoswitches. Such photoswitchable structures can be rever-
sibly isomerised by light at different wavelengths. More recently,
this approach has emerged as a powerful strategy to control a range
of different targets, including receptors and ion channels,2a,3 lipid
membranes,3 enzymes,2a,3 and nucleic acids.2a,4 So far, only a few
photoswitchable molecules have been reported to target kinases,
such as RET and BRAFV600E (Fig. 1A).5–10 The development of these
compounds has been challenging because of common photophar-
macology issues,10–12 such as insufficient isomeric enrichment in
the photo-stationary distributions (PSDs); narrow bioactive discre-
pancy between the two isomers; rapid thermal isomerization; and
reduction by, e.g., dithiothreitol (DTT) and glutathione (GSH),
which are typically used for protein stabilisation in biological
assays.
REarranged during Transfection (RET) is a kinase belonging
to the receptor tyrosine kinase family. It is essential for the
development neurons, and dysregulation of RET activity is an
important contributor to several human cancers.13 Small mole-
cule inhibitors against RET have been developed as potential
anti-cancer agents.14 Herein, we report the synthesis, photo-
physical characterisation, and biological evaluation of a photo-
switchable DFG-out kinase inhibitor, using RET as a model
target.
DFG-out kinase inhibitors (also named type II inhibitors)
represent a class of bioactive molecules that trap their target
kinases in an inactive, so-called DFG-out state, occupying a
hydrophobic pocket adjacent to the ATP binding site.15 Pona-
tinib is a DFG-out kinase inhibitor with potent activity toward
wild-type and drug-resistant gatekeeper mutations in the RET
kinase domain.16,17 Using ponatinib as the template, we
designed a potential photoswitchable DFG-out RET kinase
inhibitor (compound 8; see Fig. 1B for structure). By replacing
the acetylene moiety of ponatinib with an E-form azo bridge,
the key interactions with the adenine-binding pocket and the
geometry for triggering DFG-out conformation are preserved.
Conversely, we hypothesized that the RET kinase adenine-
binding pocket would not tolerate the inhibitor in the Z-form,
thus weakening or even losing the inhibition effect. This would
result in an inhibitor in which the stable isomer (E) is more
potent. In principle, this is a drawback, as it causes the
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molecule to be constitutively active in its thermally stable
state.18 This disadvantage is small when the Z-isomer can be
enriched almost quantitative and has very good thermal stabi-
lity. One way to circumvent this drawback would be to use the
‘‘sign inversion’’ strategy. However, this strategy relies on other
photoswitches, such as hemithioindigos and diazocines, and
these photoswitches could not be incorporated into the phar-
macophore of the DFG-out inhibitor (data not shown). We
decided to use 7-azaindole as a ‘‘head’’ group because it has
been found to be an excellent hinge-binding motif, making two
hydrogen bonds with the kinase hinge region.19,20 Further-
more, it had been reported that 7-azaindole-based azoheteroar-
ene possesses excellent photophysical properties.21 To further
evaluate our design, compounds 8E and 8Z were docked with
the RET kinase (see Fig. 1C). For this purpose, homology
modelling of the DFG-out RET structure was carried out using
KIT kinase as a template structure (PDB code 4U0I). For the
E-isomer, the 7-azaindole moiety occupies approximately the
same space as the heteroaromatic ring of ponatinib, allowing
for two hydrogen bonds with the kinase hinge region. The
E-isomer azo bridge linkage directs the remaining portion of
the molecule deep into the rear corner of the ATP-binding
pocket. Here, the phenyl ring traverses the region adjacent
to the kinase gatekeeper residue (Val105), and the 3-trifluo-
romethylphenyl aromatic ring engages the hydrophobic pocket
in the allosteric site. Importantly, the amide bond stabilizes the
outward flipping of the DFG motif. However, docking experi-
ments with the Z-isomer shows that the key interactions with
the hinge and the stabilization of the DFG-out cannot be
maintained.
Scheme 1 shows the synthetic route of target compound 8.
The aza-bridge containing moiety was prepared from 1 by an
Ullmann-type coupling, followed by a Buchwald–Hartwig cou-
pling with 3 to connect the heterocyclic head and the linker to
form the key intermediate 4.21 Subsequent Boc-deprotection,
oxidation, and removal of the tosyl group and hydrolysis of the
ester furnished 6. Finally, coupling the ‘‘tail’’ part 723 to 6
yielded the target compound 8. The HCl salt form of 8 was
prepared by treating the compound with 4 N HCl in 1,4-dioxane
and evaporating the solvent.
With the target azo compound 8 and its salt form 8HCl in
hand, their photophysical properties were studied in DMSO
and aqueous solution, respectively. As for the DMSO solution, a
thermally adapted sample (499% in the E-isomer) was first
irradiated by UV light (l = 365 nm, 14 mW cm2 for 15 seconds)
to reach a containing 97% Z-isomer (Fig. 2A) as judged by the
Fig. 1 (A) Selected azo-based photoswitchable kinase inhibitors reported in the literature; (B) DFG-out binding model of ponatinib in FGFR4 kinase (PDB
code 4UXQ), which is highly homologous to the RET kinase, inspired the design of the herein-reported photoswitchable DFG-out RET kinase inhibitor 8.
(C) Computational modelling of 8E (top) and 8Z (bottom) in the DFG-out RET kinase. The DFG-out model was obtained by homology modelling, which
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1H-NMR spectrum (Fig. S8, ESI†). This UV-enriched sample was
subsequently exposed to blue light (l = 460 nm, 12 mW cm2
for 20 seconds), yielding 64% E-isomer. The UV-vis absorption
spectra of 8HCl in H2O was recorded analogously as for 8 in
DMSO (Fig. 2B). It is worth noticing that both samples show
excellent fatigue resistance, as no significant degradation was
observed after 10 cycles of UV-vis switching (Fig. 2A and B,
insets). The thermal stability of 8Z is very good in both DMSO
and aqueous solution, displaying a thermal half-life of 377 h
and 629 h at room temperature, respectively (Fig. 2C and D).
Thus, the photophysical properties of 8 in DMSO and in
aqueous solution are comparable.
Reductive degradation is a potentially limiting factor for the
use of azobenzene photoswitches in biology,10,24 while DTT is a
reducing reagent commonly used in biochemical assays to keep
the proteins in a reduced state, and GSH is a natural antio-
xidant in mammalian cells. To ensure that the herein-reported
azo compound is stable over DTT/GSH incubation during the
biological assay described below, compound 8 was incubated
with DTT (2 mM) and GSH (10 mM) in aqueous solution,
respectively, and the stability was monitored by LC-MS. No
degradation products were detected after 18 h incubation at
room temperature (see ESI†). Subsequent UV-vis cyclicisome-
risation of 8HCl in aqueous solution containing 1 mM GSH
was performed, resulting in no detectable degradation (Fig. 3A).
In order to evaluate the inhibitory effect of 8, the compound
was tested in a biochemical ADP-Glot RET Kinase Assay. As
type II inhibitors are reported to be slow binders,25,26 a pre-
incubation step was added to the assay protocol (see ESI†). In
addition, 8 in DMSO was thermally adapted to the pure
E-isomer by heating prior to the assay, while the Z-isomer was
prepared by irradiating the serially diluted DMSO solution in a
96-well plate (4 ml in each well) with a 365 nm LED array for
15 min prior to further dilution by kinase reaction buffer. All
kinase reactions were performed at 10 mM ATP concentration.
As a result, compound 8E (IC50 = 3 nM) exhibited 17-fold more
potent activity than 8Z (IC50 = 50 nM) (Fig. 3B). The inhibitory
effect of 8E is comparable with the reference compounds
(staurosporine IC50 = 8 nM; ponatinib IC50 = 3 nM; see ESI,†
Section 4.3).
Scheme 1 Synthesis of compound 8. Reagents and conditions: (i) Boc-
hydrazide, CuI, Cs2CO3, DMSO, 50 1C, 4 h, 85%; (ii) 3, Pd(OAc)2, Xantphos,
Cs2CO3, toluene, MW, 110 1C, 2 h, 86%; (iii) DMF, MW, 180 1C, 40 min; then
O2, 100 1C, 2 h, 56%; (iv) NaOH, EtOH/H2O, 90 1C, 5 h, 92%; (v) 7, EDCHCl,
HOBt, Et3N, DCM, r.t., 36 h, 78%; (vi) 4 N HCl in 1,4-dioxane, quantitative.
Fig. 2 Photoisomerization UV-vis absorption spectrum of 8 as DMSO
solution (25 mM, A) and 8HCl in aqueous solution (25 mM, B): black line: at
thermal equilibrium. Red line: after exposure to 365 nm UV to yield the
PSD. Blue line: after exposure to 460 nm light to yield the PSD. The insets
show the absorption changes during 10 cycles of UV and vis exposure
(A and B). Thermal isomerization of the Z-isomer to the E-isomer
monitored by UV-vis absorption of 8 in DMSO (C) and 8HCl in H2O (D).
Fig. 3 (A) GSH reduction assay, 8 (35 mM) in H2O with 1% DMSO and 1 mM
GSH; (B) inhibitory concentration-response curve of E- and Z-isomer of 8
on RET activity as analysed by ADP-GloTM RET Kinase Assay; (C) photo-
switching kinetics of 8 in cell assay medium (20 mM) (D) concentration-
response curve of E- and Z-isomer of 8 as determined using NanoBRETt
TE Intracellular RET Kinase Assay in HEK293 cells transfected with
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Encouraged by these results, compound 8 was further
evaluated in a NanoBRETt TE Intracellular Kinase Assay. This
assay allows evaluating compounds that bind to a kinase
protein fused to NanoLuc luciferase in a competitive format
by using a cell-permeable fluorescent NanoBRET tracer in
HEK293 cells (human embryonic kidney cells). As shown in
Fig. 3D, the IC50 of the E-isomer was determined to be 25 nM
(incubation at 37 1C for 90 min). To evaluate the activity of the
Z-isomer, 8E was initially incubated, followed by stepwise in situ
irradiation to maximize the UV-induced PSD of the Z-isomer
throughout the incubation (see ESI,† Section 5). This irradia-
tion procedure was performed due to the relatively long resi-
dence time of the E-isomer bound in the kinase pocket when
irradiation was performed,23 and it is mostly assumed that
ligand photoswitching occurs only while the ligand is not
bound to its target.2b In addition, as shown in Fig. 3C, 35 s of
UV exposure is sufficient to switch the E-isomer to the Z-isomer-
enriched PSD in cell assay medium. Therefore, a total of 35 s of
UV light was delivered to the cells in three steps (15 s, 10 s,
10 s). An IC50 of the Z-isomer-enriched sample of 282 nM
resulted (Fig. 3D), i.e., a factor of 11 times higher than that
observed for the pure E-isomer.
In summary, we have designed and developed a practical
photoswitchable DFG-out RET kinase inhibitor derived from
ponatinib. This molecule shows efficient photoswitching to
generate a nearly pure Z-isomer in the UV-induced PSD, as
well as excellent thermal stability at room temperature. The
E-isomer potently inhibits the RET kinase with single-digit nM
IC50 in an enzymatic assay, while the UV-enriched Z-isomer
exhibited 17 times less inhibition activity. More importantly, we
can regulate the activity of the inhibitor in a cellular context by
in situ irradiation, which shows an 11-fold activity difference
between the assays with pure E-isomer and UV-enriched
Z-isomer, while the E-isomer still maintains high potency.
The almost quantitative switching of the E- to the Z-isomer
combined with the very high thermal stability of 8Z set the
stage for incubating cells with the inactive conformation and
after reaching the target site the compound can be turned ‘‘on’’
with light.18 The successful in vitro application paves the way
for further in vivo applications, e.g., in zebrafish. Furthermore,
a significant fraction of the kinome is likely targetable by type II
inhibitors,27 and this work will pave the way for developing
photoswitchable DFG-out inhibitors targeting other kinases.
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Sci. Rep., 2015, 5, 9769.
5 M. Hoorens, M. E. Ourailidou, T. Rodat, P. E. Wouden, P. Kobauri,
M. Kriegs, C. Peifer, B. L. Feringa, F. J. Dekker and W. Szymanski,
Eur. J. Med. Chem., 2019, 179, 133.
6 R. Ferreira, J. R. Nilsson, C. Solano, J. Andréasson and M. Grøtli,
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